Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Myeloma presenting during pregnancy.

Smith D, Stevens J, Quinn J, Cavenagh J, Ingram W, Yong K.

Hematol Oncol. 2014 Mar;32(1):52-5. doi: 10.1002/hon.2088. Epub 2013 Sep 1. No abstract available.

PMID:
23996410
2.

DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.

Lemaire O, Attal M, Bourin P, Laroche M.

Eur J Haematol. 2010 Mar;84(3):276-7. doi: 10.1111/j.1600-0609.2009.01372.x. Epub 2009 Nov 5. No abstract available.

PMID:
19891699
3.

[Treatment of transplant-eligible symptomatic multiple myeloma].

Nakaseko C.

Rinsho Ketsueki. 2014 Oct;55(10):2016-26. Review. Japanese. No abstract available.

PMID:
25297767
4.

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.

Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda VH, Chu CM, Kukreti V, Trudel S, Tiedemann R, Tsang R, Reece DE.

Br J Haematol. 2013 Aug;162(4):483-8. doi: 10.1111/bjh.12414. Epub 2013 Jun 15.

PMID:
23772701
5.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
6.

A new standard of care in newly diagnosed multiple myeloma.

Richardson PG.

Lancet. 2010 Dec 18;376(9758):2043-4. doi: 10.1016/S0140-6736(10)62177-0. Epub 2010 Dec 9. No abstract available.

PMID:
21146204
7.

Induction therapy for newly diagnosed multiple myeloma.

Lonial S, Miguel JF.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):19-28. Review.

PMID:
23307978
8.

[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].

de Alarcón Jiménez RM, Roca Meroño S, Alvarez Fernández GM, García Hernández MA, Navarro Parreño MJ, Jimeno Griñó C, Zarco Pedrinaci E, Molina Núñez M.

Nefrologia. 2011;31(2):238-40. doi: 10.3265/Nefrologia.pre2010.Aug.10496. Review. Spanish. No abstract available.

9.

[New treatment strategies for multiple myeloma].

Ozaki S.

Rinsho Ketsueki. 2009 Oct;50(10):1506-17. Review. Japanese. No abstract available.

PMID:
19915360
10.

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B.

Clin Lymphoma Myeloma. 2006 Nov;7(3):210-6.

PMID:
17229337
11.

[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].

Tsurumi H.

Rinsho Ketsueki. 2014 Oct;55(10):2027-35. Review. Japanese. No abstract available.

PMID:
25297768
12.

Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.

Dasanu CA, Reale MA, Bauer F.

Leuk Res. 2010 Jul;34(7):e178-80. doi: 10.1016/j.leukres.2010.01.002. Epub 2010 Jan 15. No abstract available.

PMID:
20079532
13.

[Hematopoietic stem cell transplantation for multiple myeloma].

Kanda Y.

Rinsho Ketsueki. 2009 Oct;50(10):1420-6. Review. Japanese. No abstract available.

PMID:
19915350
14.

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. doi: 10.1016/j.clml.2014.06.004. Epub 2014 Jun 11. No abstract available.

PMID:
24997557
15.

Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.

Ram R, Magen-Nativ H, Vidal L, Herscovici C, Peck A, Raanani P, Shpilberg O, Yeshurun M.

Clin Transplant. 2012 Sep-Oct;26(5):E549-54. doi: 10.1111/ctr.12018.

PMID:
23061765
16.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

17.

Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.

Schmielau J, Teschendorf C, König M, Schmiegel W, Graeven U.

Leuk Lymphoma. 2005 Apr;46(4):567-9.

PMID:
16019485
18.

Cutaneous involvement in multiple myeloma and bortezomib.

Siniscalchi A, Fratoni S, Santeusanio G, Del Poeta G, de Fabritiis P, Caravita T.

Ann Hematol. 2009 Nov;88(11):1137-9. doi: 10.1007/s00277-009-0717-7. Epub 2009 Mar 4. No abstract available.

PMID:
19259673
19.

Tandem transplants in the treatment of multiple myeloma. Pro.

Fassas AB, Tricot G.

Clin Adv Hematol Oncol. 2004 May;2(5):303-4. Review. No abstract available.

PMID:
17682284
20.

Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.

Chim CS, Choi PT, Lee WK.

Ann Hematol. 2013 Jun;92(6):855-7. doi: 10.1007/s00277-012-1639-3. Epub 2012 Nov 25. No abstract available.

PMID:
23183880

Supplemental Content

Support Center